Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 4:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 607 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo three times a day (TID) Clear all
Completed Not applicable Interventional

A Controlled Study to Evaluate the Effects of a Topical Cream on Symptoms of Arthritis, Joint, and Muscle Pain

NCT07767669
View directory record Official record
Conditions
Arthritis, Joint Pain, Muscle Pain, Musculoskeletal Pain, Joint Stiffness
Interventions
Intervention (Saje Pain Release Joint & Arthritis Cream), Placebo Comparator
Dietary Supplement
Lead sponsor
Saie Beauty
Industry
Eligibility
20 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 11, 2026, 4:12 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety, Tolerability and Pharmacodynamics of SYNB1020

NCT03447730
View directory record Official record
Conditions
Cirrhosis
Interventions
SYNB1020, Placebo
Drug · Other
Lead sponsor
Synlogic
Industry
Eligibility
18 Years to 74 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Coronado, California • Rialto, California • Charleston, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 11, 2026, 4:12 PM EDT
Completed Phase 3 Interventional Results available

Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer

NCT00369564
View directory record Official record
Conditions
Kidney Cancer, Leukemia, Lymphoma, Neurotoxicity, Peripheral Neuropathy, Sarcoma
Interventions
glutamic acid, placebo
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
3 Years to 20 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
6
States / cities
Fort Myers, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Oct 11, 2026, 4:12 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

NCT06355531
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
FNP-223, Placebo
Drug
Lead sponsor
Ferrer Internacional S.A.
Industry
Eligibility
50 Years to 80 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
12
States / cities
Carlsbad, California • San Francisco, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 11, 2026, 4:12 PM EDT
Completed Phase 3 Interventional Results available

Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain

NCT02634788
View directory record Official record
Conditions
Pain
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Phoenix, Arizona • Anaheim, California • Pasadena, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 11, 2026, 4:12 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)

NCT00810693
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Riociguat (Adempas, BAY63-2521), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
18
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 11, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol

NCT01131299
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Placebo, Alpha cyclodextrin
Other · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 11, 2026, 4:12 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Treatment of Breast Pain Using A Medication (Diclofenac) Applied to the Skin

NCT00276419
View directory record Official record
Conditions
Breast Pain, Non-cyclical Mastalgia, Surgical Scar-Related Breast Pain
Interventions
Diclofenac, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Oct 11, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Results available

Anti-LPS Antibody Treatment for Pediatric NAFLD

NCT03042767
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease (NAFLD)
Interventions
IMM-124E, Placebo
Biological · Other
Lead sponsor
Miriam Vos, MD
Other
Eligibility
6 Years to 19 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 11, 2026, 4:12 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS)

NCT02558972
View directory record Official record
Conditions
Postural Tachycardia Syndrome (POTS), Vasovagal Syncope (VVS), Fainting
Interventions
Northera (Droxidopa), Placebo
Drug
Lead sponsor
New York Medical College
Other
Eligibility
18 Years to 35 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 11, 2026, 4:12 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia

NCT01728064
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
Placebo, EPI-743 400 mg, EPI-743 200 mg
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Los Angeles, California • Tampa, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 11, 2026, 4:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses

NCT03752307
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Isoxsuprine Hydrochloride, Placebo, Corticosteroid
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 11, 2026, 4:12 PM EDT
Completed Phase 4 Interventional Results available

Phosphate Lowering in CKD Trial

NCT02209636
View directory record Official record
Conditions
Chronic Kidney Disease, Cardiovascular Disease
Interventions
Lanthanum carbonate, placebo, Ascorbic Acid, Nitroglycerin, Flow-mediated dilation measurement, Aortic pulse-wave velocity, Endothelial cell collection
Drug · Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 79 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 11, 2026, 4:12 PM EDT
Completed Phase 1 Interventional

Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis

NCT03929068
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Interventions
carbidopa-levodopa, Placebo Oral Tablet
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Oct 11, 2026, 4:12 PM EDT
Completed Phase 2 Interventional

Study of Motilitone to Treat Functional Dyspepsia

NCT02365701
View directory record Official record
Conditions
Dyspepsia
Interventions
Motilitone 30mg, Placebo
Drug
Lead sponsor
Dong-A ST Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 11, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Results available

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

NCT00853047
View directory record Official record
Conditions
Carcinoid Syndrome
Interventions
Telotristat etiprate, Octreotide LAR Depot, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
9
States / cities
Little Rock, Arkansas • San Francisco, California • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 11, 2026, 4:12 PM EDT
Recruiting Phase 1 Interventional

Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency

NCT04789148
View directory record Official record
Conditions
Vasopressin Deficiency
Interventions
Intranasal Oxytocin (IN-OXT), Placebo
Drug
Lead sponsor
Elizabeth Austen Lawson
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 11, 2026, 4:12 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Dronabinol (Oral THC) on Cannabis Use

NCT01394185
View directory record Official record
Conditions
Marijuana Smoking
Interventions
Dronabinol 120mg/day, Placebo, Dronabinol 240mg/day
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Oct 11, 2026, 4:12 PM EDT
Recruiting Phase 2Phase 3 Interventional

Cannabidiol (CBD) in Pain Reduction for Knee Osteoarthritis

NCT05020028
View directory record Official record
Conditions
Knee Arthritis
Interventions
Cannabidiol (CBD), Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 11, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Results available

CJD (Creutzfeldt-Jakob Disease) Quinacrine Study

NCT00183092
View directory record Official record
Conditions
Creutzfeldt-Jakob Disease
Interventions
Quinacrine, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 11, 2026, 4:12 PM EDT
Completed Phase 4 Interventional

Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus

NCT00207311
View directory record Official record
Conditions
Fatty Liver, Hepatitis C
Interventions
Xenical, Pegasys, Copegus, Xenicare Program
Drug · Behavioral
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 11, 2026, 4:12 PM EDT
Recruiting Phase 2 Interventional

Long Term Efficacy and Safety of Orlistat for Type 1 Hyperlipoproteinemia

NCT05816343
View directory record Official record
Conditions
Type 1 Hyperlipoprotenemia
Interventions
Orlistat, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
8 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 11, 2026, 4:12 PM EDT
Completed Phase 1Phase 2 Interventional

3VM for Treatment of Chronic Osteoarthritis Knee Pain

NCT03142178
View directory record Official record
Conditions
Arthritis, Degenerative
Interventions
Experimental: 3VM1001 active 2g Cream 3 times daily, Experimental: 3VM1001 active 3g Cream 3 times daily, Experimental: 3VM1001 active 3g Cream 4 times daily, Placebo: 3VM1001 vehicle 2g Cream 3 times daily, Placebo: 3VM1001 vehicle 3g Cream 3 times daily, Placebo: 3VM1001 vehicle 3g Cream 4 times daily
Drug
Lead sponsor
CDA Research Group, Inc.
Industry
Eligibility
40 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 11, 2026, 4:12 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil

NCT00829816
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Dimebon, Placebo
Drug
Lead sponsor
Medivation, Inc.
Industry
Eligibility
50 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Los Alamitos, California • National City, California • Delray Beach, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Oct 11, 2026, 4:12 PM EDT